[ad_1]
TORONTO, July 9, 2019 / PRNewswire / – Winterlight Labs Inc., a developer of speech-based digital biomarkers for neuropsychiatric disorders, today announced that it is developing vocal biomarkers for monitoring the evolution of neuromuscular disorders. the disease in patients with frontotemporal dementia (FTD) in collaboration with Alector, a biotechnology company developing neurodegenerative therapies.
Central nervous system (CNS) disorders, such as Alzheimer's disease, schizophrenia and depression, are badociated with changes in speech, both in terms of sound and content. Objectively measuring and badyzing speech changes with the aid of machine learning and computer linguistics is a new approach to measuring the severity of illness and could be a more sensitive monitoring the progression of the disease. This approach could help physicians and pharmaceutical companies to detect the effectiveness of treatment faster and with a higher degree of accuracy than current pen and standard paper evaluations. FTD is a rare and heterogeneous group of central nervous system disorders that progressively alters personality, behavior, and language.
Winterlight and Alector deploy Winterlight's digital speech-based biomarker on two projects. The first is an ongoing observational study of one year in participants with FTD. In this study, a caregiver remotely badesses participants for the help of a tablet evaluation of Winterlight, eliminating the need to visit a clinic.
Preliminary data from the observational study indicate that participants with primary progressive aphasia, one of the two variants of the FTD, use simpler words and grammar and are less articulate than the controls of the FTD. same age. The data in this study is intended to help develop FTD-specific digital biomarkers that could be used as an endpoint in the upcoming AL001 Phase 2 clinical trial on AL001.
About Winterlight Labs
Winterlight Labs has developed software for detecting and measuring neurological and psychiatric indications through speech using machine learning. Winterlight badyzes over 500 vocal features from the content and sound of a person's voice and creates specific biomarkers for a disease. Winterlight is currently working with Johnson & Johnson, Alector, Cortexme and several other multinational companies in the life sciences sector. Winterlight is headquartered in Toronto, Canada. For more information, please visit www.winterlightlabs.com.
SOURCE WinterLight Labs
Related Links
http://www.winterlightlabs.com
Source link
